KR20210083389A - 에스.아우레우스 연관 질병의 치료 방법 - Google Patents

에스.아우레우스 연관 질병의 치료 방법 Download PDF

Info

Publication number
KR20210083389A
KR20210083389A KR1020217020104A KR20217020104A KR20210083389A KR 20210083389 A KR20210083389 A KR 20210083389A KR 1020217020104 A KR1020217020104 A KR 1020217020104A KR 20217020104 A KR20217020104 A KR 20217020104A KR 20210083389 A KR20210083389 A KR 20210083389A
Authority
KR
South Korea
Prior art keywords
ser
gly
thr
val
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217020104A
Other languages
English (en)
Korean (ko)
Inventor
브렛 셀만
크리스틴 트카지크
멜리사 해밀턴
레이 후아
Original Assignee
메디뮨 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 엘엘씨 filed Critical 메디뮨 엘엘씨
Publication of KR20210083389A publication Critical patent/KR20210083389A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020217020104A 2012-11-06 2013-11-05 에스.아우레우스 연관 질병의 치료 방법 Ceased KR20210083389A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261723128P 2012-11-06 2012-11-06
US61/723,128 2012-11-06
PCT/US2013/068385 WO2014074470A1 (en) 2012-11-06 2013-11-05 Methods of treating s. aureus-associated diseases
KR1020207024078A KR102272744B1 (ko) 2012-11-06 2013-11-05 에스.아우레우스 연관 질병의 치료 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207024078A Division KR102272744B1 (ko) 2012-11-06 2013-11-05 에스.아우레우스 연관 질병의 치료 방법

Publications (1)

Publication Number Publication Date
KR20210083389A true KR20210083389A (ko) 2021-07-06

Family

ID=50685101

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020217020104A Ceased KR20210083389A (ko) 2012-11-06 2013-11-05 에스.아우레우스 연관 질병의 치료 방법
KR1020157011460A Ceased KR20150092738A (ko) 2012-11-06 2013-11-05 에스.아우레우스 연관 질병의 치료 방법
KR1020207024078A Active KR102272744B1 (ko) 2012-11-06 2013-11-05 에스.아우레우스 연관 질병의 치료 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020157011460A Ceased KR20150092738A (ko) 2012-11-06 2013-11-05 에스.아우레우스 연관 질병의 치료 방법
KR1020207024078A Active KR102272744B1 (ko) 2012-11-06 2013-11-05 에스.아우레우스 연관 질병의 치료 방법

Country Status (13)

Country Link
US (3) US9845348B2 (https=)
EP (1) EP2928490B1 (https=)
JP (2) JP6506172B2 (https=)
KR (3) KR20210083389A (https=)
CN (2) CN112316135A (https=)
AU (2) AU2013341421A1 (https=)
BR (1) BR112015010126B1 (https=)
CA (1) CA2890385C (https=)
ES (1) ES2912267T3 (https=)
MX (1) MX367082B (https=)
RU (1) RU2661406C2 (https=)
SG (2) SG11201503231YA (https=)
WO (1) WO2014074470A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013031485B1 (pt) 2011-06-10 2022-06-14 Medimmune, Llc Anticorpo monoclonal isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, usos e método in vitro para bloqueio ou prevenção da ligação de p. aeruginosa a células epiteliais
BR112014011028B1 (pt) 2011-11-07 2021-03-02 Medimmune, Llc anticorpo biespecífico, composição, e, uso da composição
MX375324B (es) * 2012-11-06 2025-03-06 Medimmune Llc Anticuerpos contra determinantes de la superficie de s. aureus.
US9845348B2 (en) * 2012-11-06 2017-12-19 Medimmune, Llc Methods of treating S. aureus-associated diseases
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
TW202311284A (zh) 2017-01-03 2023-03-16 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
TWI902669B (zh) 2018-07-24 2025-11-01 美商麥迪紐有限責任公司 抗金黃色葡萄球菌凝集因子a(clfa)之抗體
MX2021004114A (es) 2018-10-09 2021-07-16 Medimmune Llc Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus.
CN113164602A (zh) 2018-10-09 2021-07-23 免疫医疗有限责任公司 抗金黄色葡萄球菌抗体的组合
CN113811544A (zh) 2019-03-13 2021-12-17 免疫医疗有限责任公司 减少定殖患者中的金黄色葡萄球菌感染
CN112538112B (zh) * 2019-09-20 2023-10-27 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2043690A1 (en) * 2006-06-12 2009-04-08 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
EP2185190B1 (en) * 2007-08-31 2015-06-24 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
EP2453881A2 (en) * 2009-07-16 2012-05-23 Georgia Health Sciences University Research Institute, Inc. Porous-wall hollow glass microspheres as carriers for biomolecules
EP2284193A1 (en) * 2009-08-10 2011-02-16 Kenta Biotech AG Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
EP3470526A3 (en) * 2011-02-08 2019-07-17 Medimmune, LLC Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
AU2012214677B2 (en) * 2011-02-08 2016-11-10 Abvacc, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
MX375324B (es) 2012-11-06 2025-03-06 Medimmune Llc Anticuerpos contra determinantes de la superficie de s. aureus.
US9845348B2 (en) * 2012-11-06 2017-12-19 Medimmune, Llc Methods of treating S. aureus-associated diseases
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
US20190077851A1 (en) 2015-10-30 2019-03-14 Bruno Francois Methods of using anti-alpha toxin antibody

Also Published As

Publication number Publication date
KR20150092738A (ko) 2015-08-13
US9845348B2 (en) 2017-12-19
CN112316135A (zh) 2021-02-05
EP2928490B1 (en) 2022-03-30
EP2928490A1 (en) 2015-10-14
AU2018236849B2 (en) 2020-05-21
MX367082B (es) 2019-08-05
BR112015010126A2 (https=) 2017-08-22
US20200109191A1 (en) 2020-04-09
CN104780934A (zh) 2015-07-15
AU2013341421A1 (en) 2015-06-04
US10759849B2 (en) 2020-09-01
AU2018236849A1 (en) 2018-10-18
CA2890385C (en) 2022-07-12
ES2912267T3 (es) 2022-05-25
MX2015005481A (es) 2016-01-14
US10457724B2 (en) 2019-10-29
US20190002540A1 (en) 2019-01-03
RU2661406C2 (ru) 2018-07-16
WO2014074470A1 (en) 2014-05-15
SG11201503231YA (en) 2015-05-28
JP6506172B2 (ja) 2019-04-24
CA2890385A1 (en) 2014-05-15
RU2015121617A (ru) 2016-12-27
JP2019142888A (ja) 2019-08-29
EP2928490A4 (en) 2016-11-02
JP2015536951A (ja) 2015-12-24
HK1215173A1 (zh) 2016-08-19
US20160257733A1 (en) 2016-09-08
JP6926138B2 (ja) 2021-08-25
KR102272744B1 (ko) 2021-07-06
KR20200102533A (ko) 2020-08-31
BR112015010126B1 (pt) 2022-11-01
SG10201703677VA (en) 2017-06-29

Similar Documents

Publication Publication Date Title
KR102272744B1 (ko) 에스.아우레우스 연관 질병의 치료 방법
KR102288394B1 (ko) 스타필로코커스 아우레우스 표면 결정인자에 대한 항체
US20150044168A1 (en) Treatment of Multiple Sclerosis With Anti-CD19 Antibody
JP2022512647A (ja) 抗黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）抗体の組み合わせ
US20240109961A1 (en) Treatment of chronic prurigo
HK1215173B (en) Methods of treating s. aureus-associated diseases
TW202511292A (zh) 用於治療ＮＳＣＬＣ及ｃＨＬ之ＰＤ－１／ＴＩＭ－３結合蛋白
TW202506180A (zh) 用於癌症治療之pd-1/tigit結合蛋白
RU2808018C2 (ru) Антитела к поверхностным детерминантам s. aureus
WO2025250726A1 (en) Anti-kit antibody dosing and methods
CN119654169A (zh) 抗体-药物缀合物和双特异性检查点抑制剂的组合
CN117120089A (zh) 慢性痒疹的治疗

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210628

Application number text: 1020207024078

Filing date: 20200820

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210728

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211020

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220322

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20211020

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I